Vir Biotechnology advances VIR-5500 into expansion trials in prostate cancer

US govt signs deal with GSK and Vir Biotechnology to buy sotrovimab, a Covid-19 treatment

The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease

Study shows Glaxo-Vir drug works against Omicron mutations

Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19

GSK's antibody drug sotrovimab works against Omicron mutations

Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron